NCT00369070 is a Phase 2 clinical trial of Bevacizumab in Advanced Non-squamous NSCLC, sponsored by Amgen.

Who is sponsoring NCT00369070?

NCT00369070 is sponsored by Amgen.

What drugs are being tested in NCT00369070?

Interventions in NCT00369070: Bevacizumab, AMG 706, Paclitaxel, Carboplatin.

What condition does NCT00369070 study?

NCT00369070 studies Advanced Non-squamous NSCLC.

Is NCT00369070 still recruiting?

NCT00369070 is currently terminated. Last updated 4 January 2018.

Last reviewed 2018-01-04 · How we verify

NCT00369070

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Terminated Phase 2 Last updated 4 January 2018

What this trial tests

Phase 2 trial testing Bevacizumab in Advanced Non-squamous NSCLC in 186 participants. Terminated before completion.

Timeline

31 January 2007

Primary endpoint
23 April 2008

3 August 2011

Quick facts

Lead sponsor	Amgen
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	186
Start date	31 January 2007
Primary completion	23 April 2008
Estimated completion	3 August 2011

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
AMG 706 — full drug profile →
Paclitaxel — full drug profile →
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

Advanced Non-squamous NSCLC — all drugs for Advanced Non-squamous NSCLC →

Sponsor

Amgen — full company profile →

Who can join

18 and older, any sex, with Advanced Non-squamous NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to estimate the difference in objective response rates between each paclitaxel/carboplatin plus AMG 706 arm (Arm A and B) and paclitaxel/carboplatin plus bevacizumab arm (Arm C) in subjects with advanced non-squamous NSCLC.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
Aggarwal C, Somaiah N, Simon G. · · 2012 · cited 53× · PMID 22481432 · DOI 10.4161/cbt.19594
Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.
Kono SA, Heasley LE, Doebele RC, Camidge DR. · · 2012 · cited 46× · PMID 22165970 · DOI 10.2174/156800912799095144
Strategies targeting angiogenesis in advanced non-small cell lung cancer.
Wang J, Chen J, Guo Y, Wang B, et al · · 2017 · cited 43× · PMID 28881856 · DOI 10.18632/oncotarget.17957
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
Bass MB, Yao B, Hei YJ, Ye Y, et al · · 2014 · cited 5× · PMID 25314641 · DOI 10.1371/journal.pone.0108048

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00369070 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 4 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00369070.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing